Barriers, potential solutions, and alternatives to randomized clinical trials in male reproductive medicine


Like Comment
Related Content

Volume 111, Issue 5, Pages 871–872


Joshua A. Halpern, M.D., M.S., Robert E. Brannigan, M.D.


The field of reproductive medicine is enjoying a renaissance in advancement and innovation, as the evolution of laboratory techniques, genetic medicine, and assisted reproductive technologies (ART) have dramatically enhanced the quality of care and outcomes for patients with subfertility. From microfluidics to home semen testing, invention has rendered this an exciting time in the study of male reproductive medicine. Yet as pioneers continue to push the envelope, there remains an incomplete trail of evidence, hampering our ability to utilize these advancements in a way that will optimally serve our patients. The pace of innovation has surpassed our ability to consistently provide robust evidence for its implementation.

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.